CFM
MGX icon

Catalyst Funds Management’s Metagenomi Therapeutics MGX Stock Holding History

Catalyst Funds Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,700
Closed -$18.8K – 681
2025
Q2 		$18.8K Buy
+12,700
New +$19.9K 0.01% 426

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Catalyst Funds Management's MGX Position: Q3 2025 in Review

Catalyst Funds Management sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 12,700 shares — an estimated $18.8K sold.

Catalyst Funds Management first reported a position in MGX in Q2 2025 and held it in 1 quarter. The position peaked at $18.8K in Q2 2025. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Catalyst Funds Management reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 12,700 Metagenomi Therapeutics shares in Q3 2025, an estimated $18.8K.
  • Catalyst Funds Management first reported a position in Metagenomi Therapeutics in Q2 2025 and held it in 1 quarter.
  • Catalyst Funds Management's Metagenomi Therapeutics position peaked at $18.8K in Q2 2025.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.